New colorectal cancer drug candidate RPH-030 enters Head-to-Head trial
Disease control
Recruiting now
This study compares a new experimental drug, RPH-030, to the approved drug Vectibix in people with metastatic colorectal cancer that has a specific gene type (wild-type RAS). About 180 participants will receive either RPH-030 or Vectibix along with standard chemotherapy (FOLFIRI)…
Phase: PHASE1 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC